Key result
Systemic vaccination with norovirus virus-like particles in a humanized mouse model elicited superior mucosal IgA responses compared to IgG, providing remarkable in vivo protective function.
Why the study?
Virus-like particles provide a well-established vaccine platform, but the immunogenic properties acquired by their structure remain poorly understood.
Does systemic vaccination with norovirus VLPs improve protective IgA responses compared to disrupted VLPs in humanized and murine models?
Does systemic vaccination with norovirus VLPs improve protective IgA responses compared to disrupted VLPs in humanized and murine models?
Norovirus VLP vaccines elicit qualitatively and quantitatively superior mucosal IgA responses compared to IgG, highlighting their potential for developing effective mucosal vaccines.
Virus-like particles (VLPs) provide a well-established vaccine platform; however, the immunogenic properties acquired by VLP structure remain poorly understood. In this study, we showed that systemic vaccination with norovirus VLP recalls human IgA responses at higher magnitudes than IgG responses under a humanized mouse model that was established by introducing human PBMCs in severely immunodeficient mice. The recall responses elicited by VLP vaccines depended on VLP structure and the disruption of VLP attenuated recall responses, with a more profound reduction being observed in IgA responses. The IgA-focusing property was also conserved in a murine norovirus-primed model under which murine IgA responses were recalled in a manner dependent on VLP structure. Importantly, the VLP-driven IgA response preferentially targeted virus-neutralizing epitopes located in the receptor-binding domain. Consequently, VLP-driven IgA responses were qualitatively superior to IgG responses in terms of the virus-neutralizing activity in vitro. Furthermore, the IgA in mucosa obtained remarkable protective function toward orally administrated virus in vivo. Thus, our results indicate the immune-focusing properties of the VLP vaccine that improve the quality/quantity of mucosal IgA responses, a finding with important implications for developing mucosal vaccines.
No takes yet. Share an insight, caveat, or question.
Onodera et al. (2019) studied Norovirus infection. Norovirus virus-like particle (VLP) vaccine vs. Disrupted VLP was evaluated on IgA and IgG recall responses and virus-neutralizing activity. Systemic vaccination with norovirus virus-like particles in a humanized mouse model elicited superior mucosal IgA responses compared to IgG, providing remarkable in vivo protective function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: